[Principles of constructing synbiotic preparations, and evaluation of their clinical effectiveness].

The problem of constructing means of correction of gastrointestinal microflora is utterly important. The most promising direction here seems to be construction of synbiotics containing a multiprobiotic complex of bifidobacteria and lactobacilli, modeling the microbiocenosis of a certain age group, inulin, as a prebiotic factor and a vitamin and mineral complex. The aim of the study was to evaluate the biologically active food supplement "Normospectrum" vs. the commercial preparation "Bifidumbacterin", its ability to correct the intestinal microflora and the functional condition of the gastrointestinal tract in children. "Normospectrum" was well tolerated, favored regression of the main clinical manifestations, and had positive effect on the intestinal microbiocenosis, increasing the proportion of bifidobacteria, lactobacilli and escherichiae with full enzymatic activity, and lowering the proportion of conditionally pathogenic bacteria and fungi in the intestinal tract. The effects of "Normospectrum" on the functional disturbances of the gastrointestinal tract and the intestinal microflora were much more profound than those of "Bifidumbacterin". Good tolerance and positive effects of the new probiotic preparation "Normospectrum" on the intestinal microbiosis allows recommending it for broad clinical application in children when correction of dysbiotic shifts in the intestinal microflora is necessary.

[Experience of pediatric application of bifidumbacterin multi, a biologically active food supplement].

The article is dedicated to a clinical trial of Bifidumbacterin Multi-1, a biologically active food supplement (BAFS) for children aged 0 to 3 years. The study showed that application of BAFS in children with intestinal dysbiosis helped to cope with the symptoms of alimentary disturbances, promoted improvement of body mass index, increase of hemoglobin end erythrocyte level, suppression of zymotic and putrefactive dyspepsia, decrease of inflammation of the intestinal mucosa, elimination of bibidobacterial deficit, and reduction of conditionally pathogenic microflora. Bifidumbacterin Multi-1 was well tolerated and highly effective according to clinical and laboratory data. This preparation may be recommended as a component of complex therapy in children aged 0 to 3 years old.